Evidence map›Paper›PMID 41272190›Full record

ArticleScientific reports2025

Humoral immunity and clinical characteristics of Chinese college students experiencing a BA.5/BF.7 and XBB.1.5 wave.

Yuchen Xie, Ying Chen, Yuzhu Shi, Li Yang, Xuedong Song, Chenmin Zhang, Huixia Gao, Xiaona Du, Fumin Feng, Aidong Feng and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yuchen Xie *School of Public Health, North China University of Science and Technology, Tangshan, 063210, China.ORCID https://orcid.org/0009-0005-4614-5066
Ying Chen *Jingmen Central Hospital, Jingmen, Hubei, China.
Yuzhu Shi *School of Public Health, North China University of Science and Technology, Tangshan, 063210, China.
Li YangHebei Key Laboratory of Immune Mechanism of Major Infectious Diseases and New Technology of Diagnosis and Treatment, The Fifth Hospital of Shijiazhuang, Building No. 42 Ta'nan Road, Yuhua District, Shijiazhuang, 050021, Hebei, P. R. China.
Xuedong SongHebei Key Laboratory of Immune Mechanism of Major Infectious Diseases and New Technology of Diagnosis and Treatment, The Fifth Hospital of Shijiazhuang, Building No. 42 Ta'nan Road, Yuhua District, Shijiazhuang, 050021, Hebei, P. R. China.
Chenmin ZhangHebei Key Laboratory of Immune Mechanism of Major Infectious Diseases and New Technology of Diagnosis and Treatment, The Fifth Hospital of Shijiazhuang, Building No. 42 Ta'nan Road, Yuhua District, Shijiazhuang, 050021, Hebei, P. R. China.
Huixia GaoHebei Key Laboratory of Immune Mechanism of Major Infectious Diseases and New Technology of Diagnosis and Treatment, The Fifth Hospital of Shijiazhuang, Building No. 42 Ta'nan Road, Yuhua District, Shijiazhuang, 050021, Hebei, P. R. China.
Xiaona DuHebei Key Laboratory of Immune Mechanism of Major Infectious Diseases and New Technology of Diagnosis and Treatment, The Fifth Hospital of Shijiazhuang, Building No. 42 Ta'nan Road, Yuhua District, Shijiazhuang, 050021, Hebei, P. R. China.
Fumin FengHebei Coordinated Innovation Center of Occupational Health and Safety, School of Public Health, North China University of Science and Technology, Tangshan, 063210, China.
Aidong FengHebei Key Laboratory of Immune Mechanism of Major Infectious Diseases and New Technology of Diagnosis and Treatment, The Fifth Hospital of Shijiazhuang, Building No. 42 Ta'nan Road, Yuhua District, Shijiazhuang, 050021, Hebei, P. R. China. 13323119639@163.com.
Erhei DaiSchool of Public Health, North China University of Science and Technology, Tangshan, 063210, China. daieh2008@126.com.

Funding

The Key R&D Project of Hebei Province 22377744DThe Science and Technology Program of Shijiazhuang 231200103A
6 · The paper itself

Abstract

To investigate the humoral immunity and clinical characteristics of Chinese college students after experiencing a BA.5/BF.7 and/or XBB.1.5 wave. We enrolled 876 college students who received 2-3 vaccination doses of COVID-19 and followed by BA.5/BF.7 and/or XBB.1.5 breakthrough infections between January 2022 and October 2023. IgG and total antibodies against SARS-CoV-2 were measured by chemiluminescent immunoassay. Neutralizing antibodies were detected using a pseudovirus neutralization assay. Meanwhile, we created an Enterprise WeChat link for college students to self-report SARS-CoV-2 infections and clinical symptoms of COVID-19. We observed that among college students, the most common symptoms upon SARS-CoV-2 infection were fever, fatigue, and sore throat. Moreover, reinfected college students had higher levels of total antibodies and neutralizing antibodies against BA.5, XBB.1.5 and EG.5.1, especially after experiencing the XBB.1.5 wave. Finally, the neutralizing effect against the newly emerged Omicron subvariants XBB.1.5 and EG.5.1 is limited among the college students. Our study demonstrates that hybrid immunity, built from breakthrough infections and reinfections, enhances total antibody levels and bolsters neutralizing activity, contributing to milder clinical presentations upon reinfection. However, neutralization efficacy against newer subvariants, such as XBB.1.5 and EG.5.1, remains compromised.

Indexed as

COVID-19COVID-19 VaccinesImmunity, HumoralSARS-CoV-2AdolescentAdultAntibodies, NeutralizingAntibodies, ViralChinaFemaleHumansImmunoglobulin GMaleStudentsUniversitiesVaccinationAntibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesImmunoglobulin GAntibody responseBreakthrough infectionCollege studentsReinfectionSARS-CoV-2Symptoms

Identifiers

PMID41272190
PMCPMC12748907

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.